Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

Executive Summary

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Advertisement

Related Content

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot
Pfizer Buys Option For Vivet In Latest Gene Therapy Tie-Up
Abbott Builds Its Digital Reach In India
Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR
Servier To Tackle Parkinson's With Oncodesign Pact
Pro Vs. Con: A Side-By-Side Look At Investor Concerns, Bristol's Defenses Of Celgene Deal
Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Novartis's Farydak Enters EU As First-In-Class Myeloma Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124946

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel